Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma

Published:2016-08 Issue:4 Volume:14 Page:304-313.e6
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Mahoney Kathleen M.,Jacobus Susanna,Bhatt Rupal S.,Song Jiaxi,Carvo Ingrid,Cheng Su-Chun,Simpson Mekailah,Fay André P.,Puzanov Igor,Michaelson M. Dror,Atkins Michael B.,McDermott David F.,Signoretti Sabina,Choueiri Toni K.

Funder

Kidney Cancer Association

Genentech and Pfizer

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference33 articles.

1. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial;Escudier;J Clin Oncol,2009

2. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival;Escudier;J Clin Oncol,2010

3. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

4. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors;Motzer;Cancer,2010

5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Motzer;Lancet Oncol,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options;International Journal of Cancer;2023-10-12

2. Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma;Kidney Cancer;2022-03-15

3. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma;Kidney Cancer;2020-03-30

4. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations;Cells;2019-12-06

5. Combination of Anti-angiogenics and Other Targeted Therapies;Tumor Angiogenesis;2019